$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000119312513438247 Filed on November 12, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$14.91M	$20.23M	$16.08M
YoY Change	52.12%	25.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.800M	$2.000M	$1.500M
YoY Change	8.57%	33.33%
% of Gross Profit
Research & Development	$14.30M	$11.09M	$11.97M
YoY Change	68.24%	-7.35%
% of Gross Profit
Depreciation & Amortization	$360.0K	$316.9K	$235.5K
YoY Change	50.0%	34.52%
% of Gross Profit
Operating Expenses	$18.10M	$11.09M	$11.97M
YoY Change	49.59%	-7.35%
Operating Profit		$7.158M	$2.599M
YoY Change		175.42%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$0.00	-$554.0K	$1.557K
YoY Change	-100.0%	-35681.25%
Pretax Income	-$3.200M	$6.600M	$2.600M
YoY Change	52.38%	153.85%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%	0.0%
Net Earnings	-$3.205M	$6.604M	$2.601M
YoY Change	52.26%	153.9%
Net Earnings / Revenue	-21.5%	32.64%	16.17%
Basic Earnings Per Share	-$0.14	$0.14	$0.00
Diluted Earnings Per Share	-$0.14	$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	25.02M shares	1.185M shares	1.092M shares
Diluted Shares Outstanding		21.24M shares	21.50M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$116.5M	$33.60M
YoY Change
Cash & Equivalents	$116.5M	$33.57M	$30.45M
Short-Term Investments
Other Short-Term Assets	$1.000M	$1.100M
YoY Change
Inventory
Prepaid Expenses	$972.0K	$1.103M
Receivables	$2.004M	$2.281M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$119.5M	$36.95M
YoY Change	139.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.035M	$4.470M
YoY Change	54.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$885.0K	$147.2K
YoY Change	501.04%
Total Long-Term Assets	$6.325M	$5.022M
YoY Change	65.58%
TOTAL ASSETS
Total Short-Term Assets	$119.5M	$36.95M
Total Long-Term Assets	$6.325M	$5.022M
Total Assets	$125.8M	$41.98M
YoY Change	134.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.169M	$1.798M
YoY Change	-15.25%
Accrued Expenses	$3.584M	$939.8K
YoY Change	189.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.400M	$1.200M
YoY Change
Total Short-Term Liabilities	$28.82M	$25.27M
YoY Change	-3.05%
LONG-TERM LIABILITIES
Long-Term Debt	$8.000M	$8.400M
YoY Change
Other Long-Term Liabilities	$10.00M	$12.40M
YoY Change
Total Long-Term Liabilities	$18.00M	$20.80M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.82M	$25.27M
Total Long-Term Liabilities	$18.00M	$20.80M
Total Liabilities	$46.87M	$46.02M
YoY Change	-24.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$175.7M	-$172.5M
YoY Change	0.15%
Common Stock	$252.0K	$21.25K
YoY Change	2193.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$58.00K	$57.74K
YoY Change	0.45%
Treasury Stock Shares
Shareholders Equity	$78.91M	-$4.048M
YoY Change
Total Liabilities & Shareholders Equity	$125.8M	$41.98M
YoY Change	134.03%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$3.205M	$6.604M	$2.601M
YoY Change	52.26%	153.9%
Depreciation, Depletion And Amortization	$360.0K	$316.9K	$235.5K
YoY Change	50.0%	34.52%
Cash From Operating Activities	-$1.180M	$810.0K	-$6.320M
YoY Change	-106.67%	-112.82%
INVESTING ACTIVITIES
Capital Expenditures	-$920.0K	-$1.160M	-$280.0K
YoY Change	124.39%	314.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$920.0K	-$1.160M	-$280.0K
YoY Change	124.39%	314.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	85.02M	140.0K	10.00K
YoY Change	850100.0%	1300.0%
NET CHANGE
Cash From Operating Activities	-1.180M	810.0K	-6.320M
Cash From Investing Activities	-920.0K	-1.160M	-280.0K
Cash From Financing Activities	85.02M	140.0K	10.00K
Net Change In Cash	82.92M	-210.0K	-6.590M
YoY Change	379.31%	-96.81%
FREE CASH FLOW
Cash From Operating Activities	-$1.180M	$810.0K	-$6.320M
Capital Expenditures	-$920.0K	-$1.160M	-$280.0K
Free Cash Flow	-$260.0K	$1.970M	-$6.040M
YoY Change	-101.44%	-132.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2004Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	13604016	shares
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25020288	shares
CY2005Q2	mgnx	Additional Payment Upon Achievement Of Milestone AdditionalPaymentUponAchievementOfMilestone	10950000
CY2006Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	10003300	shares
CY2008Q3	mgnx	Onetime Milestone Payment To Be Paid Under Agreement OnetimeMilestonePaymentToBePaidUnderAgreement	5000000
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30451085
CY2012Q3	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Options Fair Market Value Of Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock	1.50
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2124624	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1855178	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2124624	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.50
CY2013Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17129782	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2877003	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	8171	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.44
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	918600	shares
CY2013Q3	us-gaap	Treasury Stock Number Of Shares Held TreasuryStockNumberOfSharesHeld	14381	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.94
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	425000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1229454
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	939811
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3396780
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15174112
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165569134
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	17390144
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1798228
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3486881
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25265811
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	625540
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-4048414
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3035013
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	679296
CY2013Q3	us-gaap	Impaired Financing Receivable Related Allowance ImpairedFinancingReceivableRelatedAllowance	0
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172528254
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	21298318
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2888688
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	21246
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41975907
CY2013Q3	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	8378184
CY2013Q3	us-gaap	Liabilities Liabilities	46024321
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3385321
CY2013Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	679296
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8812342
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3460609
CY2013Q3	us-gaap	Assets Current AssetsCurrent	36953929
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	147246
CY2013Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1103449
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	404850
CY2013Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	7522029
CY2013Q3	us-gaap	Assets Assets	41975907
CY2013Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	33974048
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33569198
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2281282
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19643994
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	12200000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4469882
CY2013Q3	mgnx	Restricted Cash Fair Value Disclosure RestrictedCashFairValueDisclosure	404850
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	17400000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164334646
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	57742
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3739125
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29728094
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14339497
CY2013Q3	mgnx	Money Market Funds Fair Value Disclosure MoneyMarketFundsFairValueDisclosure	26047169
CY2013Q3	mgnx	Preferred Stock Voting Rights As Separate Class Holding Percentage Threshold PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold	4000000	shares
CY2013Q3	mgnx	Revenue Recognition Milestone Method Revenue Receivable RevenueRecognitionMilestoneMethodRevenueReceivable	5000000
CY2013Q3	mgnx	Research And Maintenance Amount Receivable ResearchAndMaintenanceAmountReceivable	4000000
CY2003Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2051644	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55218361
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1098914	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1098914	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.94
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3249702	shares
CY2012Q4	us-gaap	Treasury Stock Number Of Shares Held TreasuryStockNumberOfSharesHeld	14381	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	425000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	628768
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1237025
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-8237308
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	52947
CY2012Q4	us-gaap	Impaired Financing Receivable Related Allowance ImpairedFinancingReceivableRelatedAllowance	0
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175472403
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	24123176
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2801653
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	10989
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53746900
CY2012Q4	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	9445171
CY2012Q4	us-gaap	Liabilities Liabilities	61984208
CY2012Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	52947
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	19956343
CY2012Q4	us-gaap	Assets Current AssetsCurrent	49927008
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	147246
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	137634
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	404850
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	18695197
CY2012Q4	us-gaap	Assets Assets	53746900
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	48148005
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47743155
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2046219
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17607293
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	57742
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3267796
CY2012Q4	mgnx	Restricted Cash Fair Value Disclosure RestrictedCashFairValueDisclosure	404850
CY2012Q4	mgnx	Money Market Funds Fair Value Disclosure MoneyMarketFundsFairValueDisclosure	29047958
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-08-14
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-13
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21908859	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20445061	shares
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-18.7739
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	687183	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0506	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12988440
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.75
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2018-01-30
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1463798	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1025933	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Substantially all of the Company’s cash and cash equivalents are maintained with major financial institutions in the United States. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> For the three and nine months ended September 30, 2013 and 2012, all of the Company’s grant revenue was related to contracts and research grants received from U.S. government agencies. Collaborations with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier), Boehringer Ingelheim GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc. (Pfizer) and Eli Lilly & Co. (Eli Lilly) account for all other revenue. All outstanding receivables are due from Gilead, Pfizer, Boehringer, Eli Lilly, and U.S. government agencies.</p> <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The following table represents the percentage of all significant revenue earned in the periods indicated:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">  </p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head --> <tr> <td width="52%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three Months Ended September 30,</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> <b>Nine Months Ended September 30,</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom"> </td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Servier</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71.3</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.2</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.6</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Boehringer</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.5</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.9</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17.2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Gilead</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.9</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Pfizer</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.5</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.3</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.4</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Government Agencies</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.5</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Eli Lilly</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55.7</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <!-- End Table Body --></table> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The following table represents the percentage of all significant accounts receivable:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">  </p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head --> <tr> <td width="64%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September 30, 2013</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31, 2012</b></td> <td valign="bottom"> </td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Gilead</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51.2</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Pfizer</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.4</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Boehringer</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Eli Lilly</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28.2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"> Government Agencies</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.4</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <!-- End Table Body --></table> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	33949	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of the financial statements in accordance with GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, convertible preferred stock and common stock, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> In addition, through September 30, 2013, the Company utilized estimates and assumptions in determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. Management uses contemporaneous valuations in estimating the fair value of its common stock. The board of directors has determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the biotechnology industry and the historic prices at which the Company sold shares of its preferred stock.</p> </div>
	us-gaap	Revenues Revenues	43128232
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-627281
	us-gaap	Licenses Revenue LicensesRevenue	42015994
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted
	us-gaap	Revenue From Grants RevenueFromGrants	1112238
	us-gaap	Operating Income Loss OperatingIncomeLoss	3571430
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	965815
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	235063
	us-gaap	Net Income Loss NetIncomeLoss	2944149
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2036700
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	626349
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20334703	shares
	us-gaap	Costs And Expenses CostsAndExpenses	39556802
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7322974
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	851183
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13968859
	us-gaap	Share Based Compensation ShareBasedCompensation	393561
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14173957
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2400000
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	194498
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-297214
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1940897
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	851183
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2036700
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32233828
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	2944149
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	834615
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-466301
	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	2944149
	us-gaap	Depreciation Depreciation	834615
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	393561
	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	87035
	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y
	mgnx	Contingent Consideration Recorded As Incremental In Process Research And Development Expense ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense	0
	mgnx	Amount Of Additional Consideration Paid Under Agreement AmountOfAdditionalConsiderationPaidUnderAgreement	0
	mgnx	Defined Contribution Plan Employees Contribution Annual Vesting Percentage DefinedContributionPlanEmployeesContributionAnnualVestingPercentage	1.00	pure
	mgnx	Preferred Stock Minimum Holding Percentage For Election Of Directors PreferredStockMinimumHoldingPercentageForElectionOfDirectors	0.6667	pure
	mgnx	Net Proceeds From Public Offering Of Common Stock NetProceedsFromPublicOfferingOfCommonStock	40000000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0118	pure
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21412848	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.51	pure
CY2006	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	460746	shares
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4752
	us-gaap	Licenses Revenue LicensesRevenue	50283510
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0557	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24281449
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1078145	shares
	us-gaap	Revenues Revenues	54027557
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted
	us-gaap	Revenue From Grants RevenueFromGrants	3744047
	us-gaap	Operating Income Loss OperatingIncomeLoss	10461830
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	69231
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2713429
	us-gaap	Net Income Loss NetIncomeLoss	10466582
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	530136
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
	us-gaap	Costs And Expenses CostsAndExpenses	43565727
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6640740
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44309
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-27935268
	us-gaap	Share Based Compensation ShareBasedCompensation	628796
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-24767276
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2400000
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	179966
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	53860
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5444288
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	44309
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-530136
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36924987
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	10466582
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	722496
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-395694
	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	10466582
	us-gaap	Depreciation Depreciation	722496
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	628796
	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	404727
	mgnx	Contingent Consideration Recorded As Incremental In Process Research And Development Expense ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense	0
	mgnx	Amount Of Additional Consideration Paid Under Agreement AmountOfAdditionalConsiderationPaidUnderAgreement	0
CY2005Q2	mgnx	Number Of Shares Issued As Additional Consideration Under Asset Purchase Agreement NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement	36135	shares
CY2008Q3	mgnx	Lease Expiration Year LeaseExpirationYear	2018
CY2002Q3	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1.00	pure
CY2002Q3	mgnx	Employee Eligible Age To Participate In Benefit Plan EmployeeEligibleAgeToParticipateInBenefitPlan	21	Age
CY2006	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease	2512390	shares
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	532654	shares
CY2010	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease	3790760	shares
CY2008	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	745716	shares
CY2008	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease	3258106	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	545970	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2012	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease	4336731	shares
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21502424	shares
CY2012Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20410117	shares
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1092307	shares
CY2012Q3	us-gaap	Revenues Revenues	16081544
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1557
CY2012Q3	us-gaap	Licenses Revenue LicensesRevenue	15532680
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted
CY2012Q3	us-gaap	Revenue From Grants RevenueFromGrants	548864
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2598957
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	2600514
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	13482587
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1514334
CY2012Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	783462
CY2012Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	48891
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11968253
CY2012Q3	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	2600514
CY2012Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	235543
CY2012Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	2600514
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	209599
CY2012Q3	mgnx	Amount Of Additional Consideration Paid Under Agreement AmountOfAdditionalConsiderationPaidUnderAgreement	0
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21242978	shares
CY2013Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20058471	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1184507	shares
CY2013Q3	us-gaap	Revenues Revenues	20232068
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	169226
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-553612
CY2013Q3	us-gaap	Licenses Revenue LicensesRevenue	20111173
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	200139
CY2013Q3	us-gaap	Revenue From Grants RevenueFromGrants	120895
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7157594
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	6603982
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	13074474
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1986555
CY2013Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	806275
CY2013Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	55311
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11087919
CY2013Q3	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	6434756
CY2013Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	316852
CY2013Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	6403843
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	135936
CY2013Q3	mgnx	Amount Of Additional Consideration Paid Under Agreement AmountOfAdditionalConsiderationPaidUnderAgreement	0

Files In Submission

Name	View Source	Status
0001193125-13-438247-index-headers.html	Edgar Link	pending
0001193125-13-438247-index.html	Edgar Link	pending
0001193125-13-438247.txt	Edgar Link	pending
0001193125-13-438247-xbrl.zip	Edgar Link	pending
d610136d10q.htm	Edgar Link	pending
d610136dex311.htm	Edgar Link	pending
d610136dex312.htm	Edgar Link	pending
d610136dex321.htm	Edgar Link	pending
d610136dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mgnx-20130930.xml	Edgar Link	completed
mgnx-20130930.xsd	Edgar Link	pending
mgnx-20130930_cal.xml	Edgar Link	unprocessable
mgnx-20130930_def.xml	Edgar Link	unprocessable
mgnx-20130930_lab.xml	Edgar Link	unprocessable
mgnx-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2013 Q4 Form 10-Q Financial Statement

#000119312513438247 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2013 Q4 Form 10-Q Financial Statement

#000119312513438247 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx